INT144652

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.55
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 3.09
Pain Relevance 2.28

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CD28) plasma membrane (CD28)
Anatomy Link Frequency
T-cell 6
CD86 2
keratinocytes 2
CD28 (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 88 98.32 Very High Very High Very High
Inflammation 19 97.16 Very High Very High Very High
rheumatoid arthritis 89 93.36 High High
antagonist 4 91.64 High High
tolerance 11 91.28 High High
psoriasis 70 88.24 High High
Pain 9 81.84 Quite High
methotrexate 118 71.04 Quite High
anakinra 7 68.56 Quite High
cytokine 34 61.64 Quite High
Disease Link Frequency Relevance Heat
Vasculitis 60 98.44 Very High Very High Very High
INFLAMMATION 19 97.16 Very High Very High Very High
Disease 111 96.20 Very High Very High Very High
Rheumatoid Arthritis 90 93.36 High High
Necrosis 14 90.88 High High
Cancer 16 90.52 High High
Psoriasis 78 88.24 High High
Apoptosis 8 87.00 High High
Systemic Lupus Erythematosus 11 86.08 High High
Urological Neuroanatomy 17 83.12 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation.
Negative_regulation (inhibiting) of CD28 Binding (interaction) of in T-cell associated with abatacept
1) Confidence 0.55 Published 2007 Journal Adv Ther Section Abstract Doc Link 17565924 Disease Relevance 0.72 Pain Relevance 0.71
Insufficient blockade of CD28/B7 interaction may partly account for the limited results obtained in NHP models.
Negative_regulation (blockade) of CD28 Binding (interaction) of
2) Confidence 0.31 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721321 Disease Relevance 0.17 Pain Relevance 0.17
CTLA4 expression therefore results in competitive inhibition of further binding with CD28, terminating T-cell activation.
Negative_regulation (inhibition) of CD28 Binding (binding) of in T-cell
3) Confidence 0.20 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936358 Disease Relevance 0.51 Pain Relevance 0.22
This agent competitively binds the B7.1 and B7.2 molecules on the surface of APCs, thereby preventing their co stimulatory interaction with CD28 on naive T cells and thus interfering with T cell activation.[26] Expression of cell surface markers like DC-LAMP, B7 and CD40 on dendritic cells and CD40 and MHC II on lesional keratinocytes was also reduced.[27] In an open label, dose-escalation, multi-center study, 43 patients with stable psoriasis vulgaris were divided into eight groups and given IV infusions of 0.5, 1, 2, 4, 8, 16, 25 and 50 mg/kg of CTLA4Ig at days 1, 2, 16, and 29.
Negative_regulation (preventing) of CD28 Binding (interaction) of in keratinocytes associated with psoriasis
4) Confidence 0.17 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.29 Pain Relevance 0.29
The agent, which binds to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and thus preventing T cell activation, acts earlier in the inflammatory cascade than do other biologic therapies by directly inhibiting the activation of T cells and the secondary activation of macrophages and B cells.
Negative_regulation (blocking) of CD28 Binding (engagement) of in CD86 associated with inflammation
5) Confidence 0.13 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833970 Disease Relevance 0.40 Pain Relevance 0.72
Abatacept, a fusion protein of CTLA4-Ig which selectively modulates T-cell co-stimulation by blocking the engagement of CD28, would theoretically be of benefit in AAV, although the EUVAS ABAVAS trial was terminated early due to slow recruitment.
Negative_regulation (blocking) of CD28 Binding (engagement) of in T-cell associated with abatacept and vasculitis
6) Confidence 0.13 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2893757 Disease Relevance 1.01 Pain Relevance 0.17

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox